Successful Treatment of Primary Cardiac Lymphoma With Monoclonal CD20 Antibody (Rituximab)

Yukinori Nakagawa; Uichi Ikeda; Masahiro Hirose; Satoshi Ubukata; Taka-aki Katsuki; Yuichiro Kaminishi; Tsutomu Saito; Mitsugu Hironaka; Tohru Izumi; Kazuyuki Shimada

doi:10.1253/circj.68.172

Case Report

Successful Treatment of Primary Cardiac Lymphoma With Monoclonal CD20 Antibody (Rituximab)

Yukinori Nakagawa, Uichi Ikeda, Masahiro Hirose, Satoshi Ubukata, Taka-aki Katsuki, Yuichiro Kaminishi, Tsutomu Saito, Mitsugu Hironaka, Tohru Izumi, Kazuyuki Shimada

著者情報

キーワード: Antibody, B cells, Cardiac tumor, Lymphoma

ジャーナルフリー

2004 年 68 巻 2 号 p. 172-173

DOI https://doi.org/10.1253/circj.68.172

詳細

抄録

Primary cardiac malignant lymphoma is extremely rare and almost all patients die within weeks. Monoclonal CD20 antibody (rituximab) was administered to a patient with primary cardiac B-cell non-Hodgkin's lymphoma expressing a CD20 molecule. The results suggest that rituximab may be a safe and effective new therapy for primary cardiac B-cell lymphoma. (Circ J 2004; 68: 172 - 173)

責任著者(Corresponding author)

J-STAGEへの登録はこちら（無料）